Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

Future Applications of Ultra-Low PSA Response

Key Themes:

• Potential use of ultra-low PSA response as a clinical trial end point
• Possibility of using PSA response to guide treatment intensification or de-escalation
• Need for further validation of this approach

Expert Insights:

• Dr Shore discussed the potential for ultra-low PSA response to serve as an end point in future clinical trials.

He highlighted how this metric could potentially influence precision medicine approaches while emphasizing the need for further validation.